#None #Vienna #Muscular Dystrophy #Edgewise Therapeutics #Sevasemten

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

Edgewise Therapeutics, Inc., listed on Nasdaq under the ticker EWTX, has announced its significant involvement at the upcoming 30th International Annual Congress of the World Muscle Society (WMS). Scheduled from October 7-11, 2025, at the Austria Centre in Vienna, the congress will serve as a prominent platform to share pivotal findings regarding Sevasemten, a groundbreaking treatment aimed at managing Becker and Duchenne muscular dystrophies (BMD and DMD).

Sevasemten, a unique oral medication, is designed to inhibit muscle damage induced by contractions, particularly in patients suffering from muscular dystrophies. The news from the company comes at a crucial time, as they prepare to present long-term data demonstrating how Sevasemten effectively stabilizes disease progression compared to traditional models of natural history in BMD. This data plays a crucial role in showcasing the treatment's potential to reshape how muscular dystrophies can be managed.

Edgewise Symposium

On Wednesday, October 8, 2025, from 7 PM CET, Edgewise will host a symposium titled "Breakthroughs in Becker: Unveiling New Natural History Insights and a Novel Agent's Clinical Progress." This session will feature keynote speakers Craig McDonald, M.D., a prominent professor and chair at the University of California Davis, who specializes in physical medicine and rehabilitation, alongside Erik Niks, M.D., Ph.D., a neurologist from Leiden University Medical Center. Attendees will have the unique opportunity to delve into the latest research findings from the CANYON and MESA trials, specifically discussing how Sevasemten aids in stabilizing individuals affected by Becker muscular dystrophy.

Scientific Posters

In addition to the symposium, Edgewise will showcase several scientific posters at the congress, which all registered attendees can view. Key presentations will include:

• - CANYON trial results: This poster will outline how Sevasemten, as an investigational fast skeletal myosin inhibitor, has been shown to significantly reduce muscle damage biomarkers and promote functional stabilization in BMD patients.
• - North Star Ambulatory Assessment tracking: This presentation will contrast the trajectory of results when using Sevasemten compared to historical data modeling in Becker muscle dystrophy, providing an insightful analysis of its effectiveness.
• - LYNX Phase 2 trial results in DMD: This poster will explore the positive effects of Sevasemten on physical functioning, detailed dosing, and its implications for future Phase 3 trials.

All posters will be presented on Friday, October 10, 2025, during Poster Session 4 from 3:45 to 4:45 PM CET.

Sevasemten Overview

Sevasemten stands at the forefront of research for its innovative mechanism of action, which is designed specifically to limit the extensive muscle damages often witnessed due to the loss or absence of the dystrophin protein. Approved by the FDA as an orphan drug for BMD and DMD, it has also received designations highlighting its significance for rare pediatric diseases and fast-track development for both conditions. The EMA has similarly acknowledged its potential through granting Orphan Drug Designation.

Through this event, Edgewise aims not only to share its research findings but also to communicate its ongoing commitment to revolutionizing therapies for patients suffering from serious muscle diseases. As clinical trials for Sevasemten advance, the company looks forward to contributing to the future landscape of muscular dystrophy treatment.

To keep up with Edgewise's latest research initiatives, detailed information about their clinical trials can be found on their official website at edgewisetx.com.

About Edgewise Therapeutics

Working at the intersection of biopharmaceuticals and muscle physiology, Edgewise Therapeutics specializes in developing innovative therapies tailored for muscular dystrophies and severe cardiac conditions. Their pipeline includes not just Sevasemten but also EDG-7500, aimed at tackling hypertrophic cardiomyopathy, and EDG-15400, targeted for heart failure treatments. With a dedicated team, Edgewise is focused on improving the lives of patients grappling with debilitating muscle diseases. For more updates, follow Edgewise on LinkedIn, X, Facebook, and Instagram.